Many targeting microRNAs' tumor drugs have entered the stage of clinical trials, for instance, MRX34 (NCT01829971, targeting miR‐34),45 Miravirsen (SPC3649, targeting miR‐122).46, 47 However, the research on targeting lncRNAs' tumor drugs is still in the stage of animal models, for example, by means of MMTV‐PyMT‐induced breast cancer mouse model, Arun et al.48 showed MALAT1 antisense oligonucleotides can slow down tumor growth and metastasis and inhibit breast cancer progression in vivo. This evidence concerns the gene MALAT1 and breast carcinoma.